Open Access Open Access  Restricted Access Subscription Access

Prevalence, Awareness, Treatment and Control of Hypertension amongst Non-Diabetic and Type 2 Diabetic Patients in Finland (19871997)

Chrysanthus Chukwuma Sr

Abstract


Aim: To assess sex-specific analyses and trends in the prevalence, awareness, treatment and control of hypertension in non-diabetic and type 2 diabetic patients. Methods: A total number of 5665 men and 6174 women of age 35-64 years in 1987, 1992 and 1997 were randomly sampled. Blood pressure measurements and a questionnaire on the presence or absence of type 2 diabetes, blood pressure history and treatment modalities were applied. Two criteria of hypertension measurements were applied based on the minimum of 130/80mmHg and maximum of 160/95mmHg. Statistical analyses were based on ANOVA or logistic regression to test the difference between study-year and age-group. Results: The prevalence rate for hypertension in non-diabetic patients decreased for both sexes within the study years, with men having the higher rates; whereas diabetic trend increased in hypertensive with the rates higher in women. Awareness of hypertension was more evident in diabetic than non-diabetic patients, with women showing more awareness. Treatment with control was better for women, and increased favorably during the years. In both sexes, diabetic patients with increased blood pressure sought treatment more than non-diabetic hypertensive. Conclusion: Pharmacological treatment modality of high blood pressure may tremendously abate morbidity and mortality in non-diabetic and diabetic individuals presenting with hypertension, but standard for optimal control of blood pressure may not be achieved in a clinical or community setting. What may be necessary are changes in lifestyle, substantial pharmacological and non-pharmacological treatment to improve the diagnosis for this extant expansive patient community.


Full Text:

PDF

References


G Hu, P Jousulahti, J Tuomilehto (2007), “Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease”, European Heart Journal, Volume 24, pp. 30593066.

C Chukwuma Sr (2018), “Convergence on the constraints and challenges in the awareness, prevention, treatment and control of type 2 diabetes and related conditions”, GJMR, Volume 17, Issue 3, Version 1.0 https://www.medicalresearchjournal.org/index.php/GJMR/article/view/1415.

D Bassi, R Cabiddu, RG Mendes, N Tossini, VM Arakelian, FCR Caruso, CR Bonjorno Jr, Arena, A Borgi-Silva (2018), “Effects of coexistence hypertension and type II diabetes on heart rate variability and cardio respiratory fitness”, Arq. Bras. Cardiol., Volume 111, Issue 1,

P Kearney, M Whelton, K Reynolds et al. (2004), “Worldwide prevalence of hypertension: a systematic review”, J Hypertens, Volume 22, Issue 1, pp. 1119.

MR Pereira, MS Coutinho, PF Freitas et al. (2007), “Prevalence, awareness, treatment, and control of hypertension in the adult population of Tubarao, Santa Catarina, Brazil, 2003”, Cad Saude Publication, Volume 23, Issue 10, pp. 23632274.

L Rampal, S Rampal, MZ Azhar, AR Rahman (2008), “Prevalence, awareness, treatment and control of hypertension in Malaysia: A national study of 16,440 subjects”, Public Health, Volume 122, Issue 1, pp. 1118.

ME De Macedo, MJ Lima, AO Silva et al. (2007), “Prevalence, awareness, treatment and control of hypertension in Portugal”, The PAP study. Rev Port Cardiol, Volume 26, Issue 1, pp. 2139.

World Hypertension League statement. Hypertension control in the world: an agenda for the coming decade. Based on the 1995 WHL Ottawa Declaration”, J Hum Hypertens, Volume 11, pp. 245247.

J Stamler, O Vacaro, JD Neaton et al. (1993), “Diabetes, other risk factors, and 12-yr cardiovascular mortality of men screened in the Multiple Risk Factor Intervention Trial”, Diabetes Care, Volume 16, pp. 434444.

C Chukwuma, Sr (1993), “Type 1 diabetic nephropathy: Clinical features and economic impact”, J Diabetes Complications, Volume 7, Issue 1, pp. 1527.

JJ Mahoney (2005), “Reducing patient drug acquisition costs can lower diabetes health claims”, Am J Manag Care, Volume 11, Issue 5, pp. S170176.

PK Whelton, FL Brancati (1993), “Hypertension management in populations”, Clin Exp Hypertens, Volume 15, pp. 11471156.

C Chukwuma Sr (1995), “Type II diabetic nephropathy in perspective”, J Diabetes Complications, Volume 9, Issue 1, pp. 5567.

A Nissinen, M Kastarinen, J Tuomilehto (2004), “Community control of hypertension–experiences from Finland”, J Hum Hypertens, Volume 18, Issue 8, pp. 553556.

MJ Kastarinen, VV Salomaa, EAVartiainen et al. (1998), “Trends in blood pressure levels and control of hypertension in Finland from 1982 to 1997”, J Hypertens, Volume 16, Issue 9, pp. 13791387.

C Gasse, HW Hense, J Stieber et al. (2001), “Assessing hypertension management in the community: trends of prevalence, detection, treatment, and control of hypertension in the MONICA Project, Augsburg 1984-1995”, J Human Hypertens, Volume 15, pp. 2736.

RB Goldberg, R Holman R, DJ Drucker (2008), “Clinical decisions. Management of type 2 diabetes”, Volume 358, Issue 3, pp. 293297.

WHO MONICA Project Principal Investigators (1988), “The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration”, J Clin Epidemiol, Volume 41, pp. 105114.

A Pajak, K Kuulasmaa, J Tuomilehto et al. (1988), “The WHO MONICA Project. Geographical variation in the major risk factors of coronary heart disease in men and women aged 35-64 years”. World Health Stat Q, Volume 41, pp. 115140.

E Vartiainen, P Jousilahti, G Alfthan et al. (2000), “Cardiovascular risk factor changes in Finland, 1992-1997”, Int J Epidemiol, Volume 29, pp. 4956.

The National High Blood Pressure Education Program Working Group (1994), “National high blood pressure education group working group report on hypertension in diabetes Hypertension”, Volume 23, Issue 2, pp. 145158.

G Lastra, S Syed, LR Kurukulasuriya, C Maarique, JR Sowers (2014), “Type 2 diabetes mellitus and hypertension: an update”, Endocrinol Metab Clin North Am, Volume 43, Issue 1, pp. 103122.

C Savoia, RM Touyz (2017), “Hypertension, diabetes mellitus, and excess cardiovascular risk: importance of baseline systolic blood pressure”, Hypertension, Volume 70, Issue 5, pp. 882883.

JR Sowers, M Epstein (1995), “Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: an update”, Hypertension,; Volume 26, Issue 6, pp. 869879.

G Bakris, J Sowers, E Murray et al. (2000), “Hypertension in patients with diabetes: why is aggressive treatment essential? Postgraduate Medicine”, Volume 107, Issue 2, pp. 5364.

MJ Glover, KJ Green lund, C Ayala, JB Croft (2005), “Racial/ethnic disparities in prevalence, treatment, and control of hypertension – United States, 1999-2002”, MMWR, Volume 54, Issue 1, pp. 79.

JM Flack, M Hamaty (1999), “Difficult-to-treat hypertensive populations: focus on African-Americans and people with type 2 diabetes”, J Hypertens Suppl, Volume 17, Issue 1, pp. 1924.

LB Signorello, DG Schlundt, SS Cohen et al. (2007), “Comparing diabetes prevalence between African Americans and Whites of similar socioeconomic status”, Am J Public Health, Volume 97, Issue 12, pp. 22602267.

WW Li, MI Wallhagen, ES Froelicher (2008), “Hypertension control, predictors for medication adherence and gender differences in older Chinese immigrants”, J Adv Nurs., Volume 61, Issue 3, pp. 326335.

JA McKnight (2000), “Managing blood pressure in type 2 diabetes”, Practical Diabetes Int., Volume 17, Issue 2, pp. 4953.

(1993), “The Sixth Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure (JNC-V)”, Arch Intern Med, Volume 153, pp. 154183.

JS Yudkin, N Chaturvedi (1999), “Developing risk stratification charts for diabetic and non-diabetic patients”, Diabetic Med., Volume 16, pp. 219227.

UKPDS (1998), “Tight blood pressure control and risk of macro vascular and micro vascular complications in type 2 diabetes”, UKPDS BMJ, Volume 38,

CJ Östgren, U Linblad, A Melander, L Råstan (2002), “Survival in Patients With Type 2 Diabetes in a Swediah Community”, Diabetes Care, Volume 25, pp. 12971302.

WJ Verberk, AA Kroon, HA Jongen-Vancraybex HA, PW de Leeuw (2007), “The applicability of home blood pressure measurement in clinical practice: a review of literature”, Vasc Health Risk Manag, Volume 3, Issue 6, pp. 959966.

D Gu, K Reynolds, X et al. for the InterAsia Collaborative Group (2002), “Prevalence, awareness, treatment, and control of hypertension in China”, Hypertension, Volume 40, Issue 920.

JA Staessen, JG Wang, L, Thijs et al. (1999), “Overview of the outcome trials in older patients with isolated systolic hypertension”, J Hum Hypertens, Volume 13, pp. 859863.

G Hu, P Jousilahti, NC Barengo (2005), “Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes”, Diabetes Care, Volume 28, Issue 4, pp. 799805.

DM Maahs, P Wadwa, D Dabelea et al. (2005), “Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population”, Diabetes Care, Volume 28, pp. 301306.

DR Berlowitz, AS Ash, EC Hickey et al. (1998), “Inadequate management of blood pressure in a hypertensive population”, N Engl J Med., Volume 339, Issue 27, pp. 19571963.

T Kauppila, MK Laine, M Honkasalo, M Raina, JG Eriksson (2016), “Contacting dropouts from type 2 diabetes care in public primary health care: description of the patient population”, Scandinavian Journal of Primary Health Care, Volume 34, Issue 3, pp. 267273.

KA Jamerson, J Basile (2008), “Prompt, aggressive BP lowering in high-risk patients”, J Clin Hypertension (Greenwich), Volume 10, Issue 1, pp. 4048.

(1993), “Joint National Committee on detection of hypertension. The 5th report of the National Committee on detection, evaluation and treatment of high blood pressure (JNC V)”, Arch Intern Med., Volume 153, pp. 154183.

G Chatellier, J Menard, C Devries et al. (1987), “Blood pressure control in a hypertension clinic”, J Hypertens, Volume 5, pp. S547S549 (Suppl).

Urqhuart J (1994), “Role of patient compliance in clinical pharmacokinetics. A review of recent research”, Clin Pharmacokinet, Volume 27, pp. 202215.

TG Pickering, GD James, C Boddie et al. (1988), “How common is white coat hypertension?”, JAMA, Volume 259, pp. 225228.

G Mancia, R Sega, C Milesi et al. (1997), “Blood-pressure control in the hypertensive population”, Lancet, Volume 349, pp. 454457.

ED Manios, EA Koroboki, GK Tsivgoulis et al. (2008), “Factors influencing White-coat Effect”, Am J Hypertens, (Epub ahead of print).

K Eguchi, S Hoshide, J Ishikaw et al. (2008), “Cardiovascular prognosis of sustained and white-coat hypertension in patients with type 2 diabetes mellitus”, Blood Press Monit, Volume 13, Issue 1, pp. 1520.

SM Saleem, SMS Khan, SS (Jan 2017), “Finnish Diabetic Risk Score: A tool for predicting risk of undiagnosed type 2 diabetes mellitus”, Ann Med Health Sci Res, Volume 7, pp. 295298.

M Fize'lova, R Jauhiainen, A Stancakova, J Kuusisto, M Laakso (2019), “Finnish Diabetes Risk Score is associated with impaired insulin secretion and insulin sensitivity, drug-treated hypertension and cardiovascular disease: A follow-up study of the METSIM Cohort”, PLoS ONE, Volume 11, Issue 11, DOI: 10.1371/journal.pone.01665849.


Refbacks

  • There are currently no refbacks.